Navigation Links
Arcadia Resources Announces First Quarter Results
Date:8/13/2009

---- Revenues, net $26,409 $26,778 Cost of revenues 18,961 18,668 ------ ------ Gross profit 7,448 8,110 Selling, general and administrative 9,666 10,244 Depreciation and amortization 411 459 --- --- Total operating expenses 10,077 10,703 Operating loss (2,629) (2,593) Other expenses: Interest expense, net 838 956 Loss on extinguishment of debt - 248 Other 36 10 -- -- Total other expenses 874 1,214 --- ----- Loss from continuing operations before income taxes (3,503) (3,807) Income tax expense 93 196 -- --- Loss from continuing operations (3,596) (4,003) Discontinued operations: Income / (loss) from discontinued operations (1,193) 717 Net gain on disposal 216 - --- - (977) 717
'/>"/>
SOURCE Arcadia Resources, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Arcadia Completes New Financing; Previews Fourth Quarter Results
2. Arcadia Resources Announces Sale of Non-Strategic Businesses
3. Plane Crash Claims Arcadians Chairman and Founder, John H. Austin M.D.
4. Arcadia Resources Announces Webcast of its Fiscal 2009 Fourth-Quarter and Year-End Conference Call
5. Arcadia Resources Sells Non-Core Software Business
6. Arcadian Management Services Names CEO Robert Fahlman as Chairman of the Board
7. Arcadia Resources Responds to Share Price Volatility
8. Arcadia HealthCare Names Former Walgreens Executive Charles Goodall as Vice President of DailyMed(TM) Pharmacy Operations
9. WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety, Efficacy and Compliance for Medicaid Members
10. Arcadia Resources Announces Fourth Quarter and Fiscal 2009 Year-End Results
11. Arcadian Chairman and Chief Executive Officer, Robert Fahlman, to Present at Focus on Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Green Bridge Industries Inc to Exhibit ZAP 28TM 29 Stain Remover Pen at the L A County Fair 56267 1Green Bridge Industries Inc to Exhibit ZAP 28TM 29 Stain Remover Pen at the L A County Fair 56267 2Surgical scrub solution 3A Its good for patients too 56263 1Surgical scrub solution 3A Its good for patients too 56263 2Surgical scrub solution 3A Its good for patients too 56263 3Surgical scrub solution 3A Its good for patients too 56263 4GENova names Dr John Savin as Vice President 56261 1GENova names Dr John Savin as Vice President 56261 2